

**RECEIVED**

ATTORNEY DOCKET NO. 01113.0001U3

APR 10 2002

CONFIRMATION NO. 4473

TECH CENTER 1600/2900

Page 1 of 2

#5

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 7-80) PATENT AND TRADEMARK OFFICE  <b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTORNEY DOCKET NO.:</b> 01113.0001U3	<b>SERIAL NO.</b> 09/991,258 <b>CONFIRMATION NO.</b> 4473
	<b>APPLICANT:</b> Olmsted et al.	
	<b>FILING DATE:</b> November 16, 2001	<b>GROUP:</b> 1642

U.S. PATENT DOCUMENTS							
EXAMINER INITIALS		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)		
hgf	A1	Betts et al. Cross-Clade Human Immunodeficiency Virus (HIV)-Specific Cytotoxic T-Lymphocyte Responses in HIV-Infected Zambians. <i>J. Virol.</i> 71(11):8908-8911 (1997)
	A2	Caley et al. Humoral, Mucosal, and Cellular Immunity in Response to a Human Immunodeficiency Virus Type 1 Immunogen Expressed by a Venezuelan Equine Encephalitis Virus Vaccine Vector. <i>J. Virol.</i> 71(4):3031-3038 (1997)
	A3	Davis et al. <i>In Vitro</i> Synthesis of Infectious Venezuelan Equine Encephalitis Virus RNA from a cDNA Clone: Analysis of a Viable Deletion Mutant. <i>Virology</i> 171:189-204 (1989)
	A4	Davis et al. In Vitro Synthesis of Infectious Venezuelan Equine Encephalitis Virus RNA from a cDNA Clone: Analysis of a Viable Deletion Mutant and Mutations Affecting Virulence. <i>Vaccines</i> 90:109-113 (1990)
	A5	Davis et al. Attenuating Mutations in the E2 Glycoprotein Gene of Venezuelan Equine Encephalitis Virus: Construction of Single and Multiple Mutants in a Full-Length cDNA Clone. <i>Virology</i> 183:20-31 (1991)
	A6	Davis et al. Attenuated Mutants of Venezuelan Equine Encephalitis Virus Containing Lethal Mutations in the PE2 Cleavage Signal Combined with a Second-Site Suppressor Mutation in E1. <i>Virology</i> 212:102-110 (1995)
	A7	Davis et al. A Viral Vaccine Vector That Expresses Foreign Genes in Lymph Nodes and Protects against Mucosal Challenge. <i>J. Virol.</i> 70(6):3781-3787 (1996)
	A8	Davis et al. Immunization against influenza with attenuated Venezuelan equine encephalitis virus vectors. In: <u>Options for the Control of Influenza III</u> . L. E. Brown and A. W. Hampson, eds. Elsevier, Amsterdam pp. 803-809 (1996)
	A9	Davis et al. Vaccination of Macaques against Pathogenic Simian Immunodeficiency Virus with Venezuelan Equine Encephalitis Virus Replicon Particles. <i>J. Virol.</i> 74(1):371-378 (2000)
	A10	Grieder et al. Specific Restrictions in the Progression of Venezuelan Equine Encephalitis Virus-Induced Disease Resulting from Single Amino Acid Changes in the Glycoproteins. <i>Virology</i> 206:994-1006 (1995)
	A11	Hevey et al. Marburg virus vaccines: comparing classical and new approaches. <i>Vaccine</i> 20:586-593 (2002)
	A12	Hirsch et al. Patterns of Viral Replication Correlate with Outcome in Simian Immunodeficiency Virus (SIV)-Infected Macaques: Effect of Prior Immunization with a Trivalent SIV Vaccine in Modified Vaccinia Virus Ankara. <i>J. Virol.</i> 70(6):3741-3752 (1996)




#5

RECEIVED

ATTORNEY DOCKET NO. 01113.0001U3  
SERIAL NO. 09/991,258  
APR 10 2002  
CONFIRMATION NO. 4473  
Page 2 of 2  
TECH CENTER 1600/2900

A13	Johnston and Smith. Selection for Accelerated Penetration in Cell Culture Coselects for Attenuated Mutants of Venezuelan Equine Encephalitis Virus. <i>Virology</i> 162:437-443 (1988)
A14	Johnston and Peters. Alphaviruses. <i>Fields Virology</i> , 3rd ed., Lippincott-Raven Publishers, Philadelphia, Chapt. 28 pp. 843-898 (1996)
A15	Kinney et al. The Full-Length Nucleotide Sequences of the Virulent Trinidad Donkey Strain of Venezuelan Equine Encephalitis Virus and Its Attenuated Vaccine Derivative, Strain TC-83. <i>Virology</i> 170:19-30 (1989)
A16	Kinney et al. Attenuation of Venezuelan Equine Encephalitis Virus Strain TC-83 Is Encoded by the 5'-Noncoding Region and the E2 Envelope Glycoprotein. <i>J. Virol.</i> 67(3):1296-1277 (1993)
A17	Paredes et al. Three-dimensional structure of a membrane-containing virus. <i>Proc. Natl. Acad. Sci. USA</i> 90:9095-9099 (1993)
A18	Pushko et al. Replicon-Helper Systems from Attenuated Venezuelan Equine Encephalitis Virus: Expression of Heterologous Genes <i>in Vitro</i> and Immunization against Heterologous Pathogens <i>in Vivo</i> . <i>Virology</i> 239:389-401 (1997)
A19	Schlesinger and Schlesinger. Togaviridae: The Viruses and Their Replication. <i>Fields Virology</i> , 3rd. edition. (Fields et al., ed) Lippincott-Raven Publishers, Philadelphia (1996)
A20	Strauss and Strauss. The Alphaviruses: Gene Expression, Replication, and Evolution. <i>Microbiol. Rev.</i> 58(3):491-562 (1994)
A21	Strauss and Strauss. Alphavirus proteinases. <i>Virology</i> 1:347-356 (1990)
EXAMINER:	DATE CONSIDERED: 6/29/03
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



ATTORNEY DOCKET NO. 01113.0001U3  
SERIAL NO. 09991,258  
Page of 2

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 7-80) PATENT AND TRADEMARK OFFICE  LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)	ATTORNEY DOCKET NO.: 01113.0001U3	SERIAL NO. 09991,258
	APPLICANT: Olmsted et al.	
	FILING DATE: November 16, 2001	GROUP: 1642

U.S. PATENT DOCUMENTS							
EXAMINER INITIALS		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B1	6,426,196 B1	07/30/2002	Dubensky, Jr. et al.	435	69.1	
	B2	6,391,632 B1	05/21/2002	Dubensky, Jr. et al.	435	325	
	B3	6,376,236 B1	04/23/2002	Dubensky, Jr., et al.	435	320.1	
	B4	6,342,372 B1	01/29/2002	Dubensky, Jr., et al.	435	69.1	
	B5	6,329,201 B1	12/11/2001	Polo et al.	435	320.1	
	B6	6,261,570 B1	07/17/2001	Parker et al.	424	205.1	
	B7	6,242,259 B1	06/05/2001	Polo et al.	435	456	
	B8	6,224,879 B1	05/01/2001	Sjöberg et al.	424	218.1	
	B9	6,190,666 B1	02/20/2001	Garoff et al.	424	208.1	
	B10	6,156,558	12/05/2000	Johnston et al.	435	235.1	
	B11	6,146,874	11/14/2000	Zolotukhin et al.	435	235.1	
	B12	6,015,694	01/18/2000	Dubensky, Jr. et al.	435	69.3	
	B13	6,015,686	01/18/2000	Dubensky, Jr. et al.	435	69.1	
	B14	6,008,035	12/28/1999	Johnston et al.	435	235.1	
	B15	5,843,723	12/01/1998	Dubensky, Jr. et al.	435	69.3	
	B16	5,814,482	09/29/1998	Dubensky, Jr. et al.	435	69.3	
	B17	5,811,407	09/22/1998	Johnston et al.	514	44	



#6

RECEIVED  
AUG 15 2002  
ATTORNEY DOCKET NO. 01M/00001U3  
SERIAL NO. 09991,258  
Page 2 of 2  
TECH CENTER 1600/2900

147	B18	5,792,462	08/11/1998	Johnston et al.	424	199.1	
	B19	5,789,245	08/04/1998	Dubensky, Jr. et al.	435	320.1	
	B20	5,766,602	06/16/1998	Xiong et al.	424	218.1	
	B21	5,739,026	04/14/1998	Garoff et al.	435	240.2	
	B22	5,643,576	07/01/1997	Johnston et al.	424	199.1	
	B23	5,639,650	06/17/1997	Johnston et al.	435	236	
	B24	5,505,947	04/09/1996	Johnston et al.	424	218.1	
✓	B25	5,185,440	02/09/1993	Davis et al.	536	237.2	

## FOREIGN PATENT DOCUMENTS


## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)


147	B26	Barouch et al. "Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys" <i>PNAS</i> , 97(8):4192-4197, April 2000					
	B27	Sykes and Johnston "Genetic Live Vaccines Mimic the Antigenicity But Not Pathogenicity of Live Viruses" <i>Dna and Cell Biology</i> , 18(7):521-531, 1999					
	B28	Feyzi et al. "Structural Requirement of Heparan Sulfate for Interaction with Herpes Simplex Virus Type 1 Virions and Isolated Glycoprotein C" <i>The Journal of Biological Chemistry</i> , 272(40):24850-24857, October 1997					
	B29	Suomalainen et al. "Spike Protein-Nucleocapsid Interactions Drive the Budding of Alphaviruses" <i>Journal of Virology</i> , 66(8):4737-4747, August 1992					
✓	B30	Smerdou and Liljeström "Two-Helper RNA System for Production of Recombinant Semliki Forest Virus Particles" <i>Journal of Virology</i> , 73(2):1092-1098, February 1999					

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED  
APR 23 2003  
TECH CENTER 1600/2900



6/29/03

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.